MIH
ATOS icon

Meitav Investment House’s Atossa Therapeutics ATOS Stock Holding History

Meitav Investment House’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,000
Closed -$63K – 415
2021
Q1 		$63K Buy
+2,000
New +$73.1K ﹤0.01% 375

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Meitav Investment House's ATOS Position: Q2 2021 in Review

Meitav Investment House sold out of Atossa Therapeutics (ATOS) in Q2 2021, closing a stake of 2,000 shares — an estimated $63K sold.

Meitav Investment House first reported a position in ATOS in Q1 2021 and held it in 1 quarter. The position peaked at $63K in Q1 2021. 86 funds tracked by Wall St. Rank hold ATOS as of Q2 2021.

  • Meitav Investment House reported no remaining Atossa Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Meitav Investment House sold 2,000 Atossa Therapeutics shares in Q2 2021, an estimated $63K.
  • Meitav Investment House first reported a position in Atossa Therapeutics in Q1 2021 and held it in 1 quarter.
  • Meitav Investment House's Atossa Therapeutics position peaked at $63K in Q1 2021.
  • 86 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2021.

Based on Meitav Investment House's 13F filing for Q2 2021, filed 5 Aug 2021.